Chemoradiotherapy
Phase 3 trial for locally advanced head and neck cancer terminated
A randomized phase 3 study designed to evaluate the addition of avelumab to chemoradiotherapy for patients with untreated locally advanced head and neck squamous cell carcinoma has been terminated based on the recommendation of the independent data monitoring committee.
FDA grants breakthrough therapy designation to Debio 1143 for head and neck cancer
The FDA granted breakthrough therapy designation to Debio 1143 for first-line treatment of head and neck cancer, according to the agent’s manufacturer.
Proton chemoradiotherapy associated with reduced acute adverse events in locally advanced cancer
Proton chemoradiotherapy appeared associated with a substantial reduction in acute adverse events that caused unplanned hospitalizations compared with traditional photon chemoradiotherapy among adults with locally advanced cancer, according to results of a retrospective study published in JAMA Oncology.
Formulation could reduce toxicities of head and neck cancer chemoradiotherapy
Researchers at Purdue University and Indiana University School of Medicine have developed a novel chemoradiotherapy formulation that could decrease treatment-associated adverse events among patients with advanced head and neck cancer.
De-intensified chemoradiotherapy confers favorable outcomes in HPV-associated oropharyngeal cancer
A de-intensified chemoradiotherapy regimen conferred favorable clinical outcomes among patients with HPV-associated oropharyngeal squamous cell carcinoma, according to results of a single-arm phase 2 study published in Journal of Clinical Oncology.